ArticleBMC anesthesiology2026
Age‑stratified median effective dose (ED₅₀) of remimazolam besylate for successful gastroscope insertion without body movement in geriatric patients.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRemimazolam besylate is increasingly used for procedure sedation anesthesia (PSA) in gastrointestinal endoscopy, but age‑specific dosing for elderly patients is unclear. This study determined the median effective dose (ED₅₀) for successful gastroscope insertion without patient movement in two geriatric age groups.
methodsIn a prospective single‑center trial, 51 patients were assigned by age to Group L (65-70 years, n = 27) or Group H (> 70 years, n = 24). All received 0.1 µg/kg sufentanil, followed by an initial remimazolam bolus of 0.15 mg/kg (Group L) or 0.10 mg/kg (Group H). Doses were adjusted in 0.02 mg/kg steps using a modified Dixon up‑and‑down method based on the previous patient's response (movement vs. no movement). Primary outcome was ED₅₀ for successful insertion. Secondary outcomes were the induction time, hemodynamic changes, hypoxemia, and other adverse events.
resultsED
conclusionsFor elderly patients undergoing gastroscopy, the ED₅₀ of remimazolam is 0.171 mg/kg for ages 65-70 and 0.098 mg/kg for > 70 years combined with 0.1 µg/kg sufentanil. These ED
trial registrationChinese Clinical Trial Registry, No:ChiCTinR2500110081. Registered on 30 September 2025. Prospective registration. http://www.chictr.org.cn .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.